Pulmonary Hypertension Network Australia inspire.enable.support
Find us on Facebook
  • About Us
    • Contacts >
      • Contact PHNA
      • Contact other PH & Lung Organisations
      • Online Facebook, Websites & Organisations
    • Who are PHNA
    • Organisational Chart
    • Patron & Ambassadors
    • Goal, Purpose, Vision & Mission
    • Governance
    • Strategic Plan 2018/19 >
      • 2019
    • Projects 2019
    • The Pledge Fundraising
    • Funding/Sponsors/Affiliates
    • Awards & Professional Development
  • Information
    • Australian Charter Healthcare Rights
    • PH Glossary of Terms
    • Surgery & PH
    • Over the counter medications
    • Colds, Flu and Pneumonia
    • PH Acronym Decoder
    • Service or Therapy Dogs & Lung Disease
    • PH & Life Expectancy
    • Salt, Nutrition, Recipes >
      • Nutritionist Zoe Bingley-Pullin
      • Eat Brighter, Live Brighter
      • Salt, Fluid & Diuretics
      • PH, Diet & Nutrition
      • Jamie Oliver - Chef - Author - Super Foods
      • Lifestyle & Foodie Donna Hay
    • Sex differences and PAH study
    • Emergencies
    • Invisible Diseases
    • Organ Donation & Transplant
    • Donate Life Australia
    • Dying to Live Documentary about the Journey of Organ Donation
    • PH Resources Translated
    • Virtual PAH
    • PHuman inspired by Actelion
    • Lung Foundation Australia
  • Support
    • RESOURCES >
      • Resource Shop General >
        • PHNA Patient Pack, Awareness Kit & Resources
        • Lung Foundation Australia
        • PHA Canada
        • PHA USA
        • phaware.global (USA)
        • PHA United Kingdom
        • PHA Europe
    • PHNA - Community Support Group WA
    • Support Groups Nationwide & Support Group Services
    • Person/Patient Centred Care
    • Comprehensive Care Plans
    • Patient Advocates >
      • Setting the limits on advocacy AMA
    • Advance Care Planning
    • Palliative Care >
      • Lung foundation Australia
      • Palliative Care WA
    • Your Life Assist - Your Life Talks
    • NAIDOC
    • Patient Opinion
    • Health Consumers Council Patient Experience Week >
      • Patient Experience Week 2018
      • Patient Experience Week 2019
    • Health Consumers Rights & Information
    • Health Engagement Network
    • ConnectGroups Support Database WA
    • Support Services at a Glance
    • Lung Foundation Australia
    • Scleroderma Australia
    • Carers Australia & National Associations >
      • Carers Information & Articles
    • Silverchain Group Australia
    • Arthritis & Osteoporosis Foundation WA
    • Services & Equipment for sale or hire
  • Lifestyle Series
    • Calm Moment with Natalie Lue
    • Creative Expressive Therapies
    • Sense & Style
    • Lifestyle Series >
      • Spoon Theory
      • GoodHealth Keeping track of your spoons
      • Procrastination, why do we do it?
      • Eating better for mental health
      • Declutter in a day!
      • Wearing Oxygen - Life Lessons
      • Managing your long term chronic condition video clips
      • PH and Dating
      • Mindful Living
      • Brain Fog
      • Mental Health Moment
      • Confidence Boosting Exercises
    • Exercise & PH
    • Pregnancy, Intimacy & Sex >
      • Your sex life
    • Living Better with PH Series
    • Coping when your newly diagnosed
    • Letter to my Lungs Activity
    • Counselling & Motivational Tips
    • Day to Day Living with PH
    • Coping with PH Long Term
    • Emotional Wellbeing
    • Identifying & Seeking Treatment for Depression
    • Bereavement , Grief & Loss
    • Children and Teens
    • Men and PH
    • PH & the elderly
    • Living and Coping with PH
    • Allergies & Hayfever
  • Community Spotlight
    • Magazine & YouTube >
      • Magazine & eNews >
        • Archived Earlier Editions
      • Monthly Blog Update >
        • Blog 2019
      • The Quirky Collective Writers Club >
        • Stories
      • YouTube - Lifestyle & Education
      • Pulmonary Hypertension News.Com
      • The PH Bloggers
      • Self Help to watch & read
      • Network Partners FB, Blogs, Subscriptions
      • Lauren Rowe - Transplant Recipient Motivation Clips
      • The Mighty Bloggers
    • We are PHamily
    • PH Angels
    • My Story
    • Artists & Authors >
      • Artists
      • Authors
      • Musical Artists
      • Print
      • Film
    • Patient View
    • phaware.global >
      • About Lucas & Steve
      • The phaware Campaign
      • The phaware Gallery
  • Understanding PH Definition
    • Medical Tests, All about PH/PAH >
      • Medications & Pharmacy >
        • Medications & Treatments in Australia
        • Forms & Scripts & Toolkits
        • Pharmaceutical and Specialty Pharmacy Companies
      • Blood Tests, INR & Blood Thinners
      • X-Rays, Scans & More
      • Six Minute Walk Test
      • Oxygen Therapy
      • Pulmonary Function Tests
      • Echo Cardiogram
      • Q&A - Monitoring & Follow-up
      • Exercise Induced PH Tests
      • Right Heart Catheter
      • Mild Pulmonary Hypertension
      • Oxygen, Travel, Altitude >
        • Altitude
      • Getting a Second Opinion
    • Signs & Symptoms of PH
    • Classification of PH
    • Types & Causes of PH
    • Who does PH affect?
    • Higher Risk Related Diseases & PH
    • Pulmonary Hypertension Treatments
    • Pulmonary Hypertension Treatments PBS
    • Life Expectancy & Prognosis
    • Do I or Don't I have Pulmonary Hypertension?
    • How am I doing? Assessing your PAH/PH
Picture
Major Developments in Pulmonary Hypertension Affecting Prognosis

​1.     Approval of initial therapy with Letairis and Adcirca - The AMBITION Study has reinforced the importance of an aggressive early regimen for the treatment of PAH.  Although this study did not prove a mortality benefit, there were dramatic improvements in clinical worsening.

2.  Availability of oral prostanoid medications (Orenitram and Uptravi) Orenitram’s approval though an exciting development does not translate in measured improvements in outcomes for most patients studied.  We should be cautious with this agent.  In contrast, Uptravi was shown to reduce rates of clinical worsening in PAH patients.

3.     New data published about the role of anticoagulation - Two recent publications attempted to shed light on the role of anticoagulation in PAH.  Unfortunately, the message was very confusing for patients with idiopathic PAH.  For patients with other types of PAH, the message was more consistent—no advantage to anticoagulation.

The Best Data Available to Determine Life Expectancy in Pulmonary Hypertension - We first need to acknowledge that we do not have a good way of predicting any one patient’s life expectancy.  What we do have are data that look at several large groups of patients over many years.  These data were collected for the most part in the early 2000’s as part of the Reveal Registry and thus do not reflect today’s best care.  What this data showed us is that in this group of 2,635 patients, overall one year survival was 85%, three year survival was 68%, five year survival was 57% and seven year survival was 49%.
​
A closer look at this data also showed us that certain characteristics predict a greater likelihood of doing poorly.  These characteristics are lumped together under the term “high risk features”.  Certain characteristics predict a much better course and are termed “low risk features”.
Picture
​How Long Can I Expect to Live with Pulmonary Hypertension?

Although pulmonary arterial hypertension was discovered in 1891, there were no known treatments for the disease until 1994 when Flolan was introduced. Prior to the release of that medication, the prognosis and life expectancy for a patient with pulmonary hypertension was around 3 years and it took an average of 2 years to accurately diagnose a patient. Flolan was the first drug to increase the life expectancy by up to 5 years for pulmonary hypertension patients. While we do not currently have a cure for the disease, several more treatments have been approved for PAH thanks to research. Over the past 20 years, we have gone from no medications to treat PAH to over 10 medications. Even more medications are being studied. We are optimistic that our patients will continue to experience longer survival and better quality of life.

To reiterate, no doctor has a crystal ball. However, in general, patients that fit into the low risk group (above) live more than 10 years. As patients begin to acquire more and more high risk features, survival declines. In my patients that have all of the high risk features, despite my most aggressive combination of medications, we often begin talking about lung transplantation.

Researching Treatments and a Possible Cure for Pulmonary Hypertension

The best news of all for patients with PAH is that we have a rich pipeline of new medications being studied for PAH. We remain very optimistic that we will continue to improve our patient’s survival. I encourage my patients to be part of the process of improving patient outcomes by participating in clinical research trials.

Key players in Research for Pulmonary Hypertension

The advancements in treating pulmonary hypertension patients would not have been possible without research. There are several key players in bringing a drug to market or making it available for patients. The drug companies who set up the research study for the specific drug, the pulmonary hypertension centers that become participating sites for the studies, and most importantly the pulmonary hypertension patients who enroll in the research studies.  Research is such an important piece of bringing new therapies to market that the PHA (Pulmonary Hypertension Association) requires all of their Comprehensive Care Centers to have a fully functioning research department.

Who can Participate in Pulmonary Hypertension Research

Each research study has strict rules about what types of patients can be enrolled, how the drug will be administered, and what measurements will be used to determine the results of the study. Many of the studies have requirements of what background therapy a patient can be on before they are enrolled in the study. For example, protocol (rules of the study) might say a patient cannot be on any treatments for pulmonary hypertension prior to enrolling in the study or protocol might say they can be on Adcirca or Revatio but not Letairis or Tracleer. It is becoming more and more difficult to find pulmonary arterial hypertension patients to enroll in studies as many of them are starting therapies with physicians outside of specialty clinics and disqualifying themselves as research candidates.

Steps to Participating in Research for Pulmonary Hypertension

Most pulmonary hypertension centers of excellence participate in research studies. If the physician you are currently working with does not participate, inform them that you would like to learn more about research studies for treatments for pulmonary hypertension. They may be able to refer you to a center currently enrolling patients in studies.

Research is completely separate from clinical management of the patient, meaning your current physician will continue to participate in your care. It is important for potential research patients to understand the risks and benefits of enrolling in a research study and what will be expected of them throughout the study. The patient will be asked to take home information about the study and read through it and come back to discuss any questions or concerns. Once all of their questions are answered they will be asked to sign an informed consent if they are interested in participating. It is important to understand that while a physician may offer the patient the chance to participate in a study, the decision is always up to the patient. Some patients will want to participate in research but not fit the specific rules of the current research studies enrolling. The sponsor (usually a drug company) of the study is ultimately responsible for deciding which patients are eligible to enroll. Once you are enrolled in a research study, you may choose to stop at any time. This is called withdrawing consent. You will not be punished or suffer any negative consequences from your doctor if you choose to stop participating. Some studies last a few months and others last many years.
​
We are very excited about research. Through your participation we are able to improve the care of all patients with PAH.
​
Picture
ACKNOWLEDGEMENT: "The Network" would like to acknowledge Aboriginal and Torres Strait Islander peoples as Australia's First People and Traditional Custodians. We value their culture, identities, and continuing connection to country, waters, kin and community. We pay our respects to Elders, past and present, and are committed to making a positive contribution to the well-being of Aboriginal and Torres Strait Islander young people, by working on providing services that are welcoming, safe, culturally appropriate and inclusive.  PHNA is committed to embracing diversity and eliminating all forms of discrimination in the provision of health services. PHNA welcomes all people irrespective of ethnicity, lifestyle choice, faith, sexual orientation and gender identity. 

DISCLAIMER: The information provided on the PHNA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified medical professionals who are familiar with your individual needs. PHNA does not endorse or recommend any commercial products or services. We provide information only with responsibility being on the part of the user. PHNA does not accept any responsibility for any websites advertised if the user incurs spam/virus or other. All our information is shared in good faith and without prejudice.  

PHNA proudly share educational information and resources with you from various sectors and access other information from many other reputable PH & associated organisations. All logo's, photographs, organisation produced resources are subject to copyright and cannot be used without prior written permission from PHNA. Some images belong to PHNA, or other organisations, some are from google and we give full credit to the authors/artist/designers.  The PHNA website is hosted through Weebly and designed and maintained by PHNA. All rights reserved 2019.
​
HQ:  facebook.com/pulmonaryhypertensionna - phnaustralia@gmail.com
​Provide Feedback & Report Bugs​